Siegfried Transfers A Plant To Celgene | Chemical & Engineering News
Volume 93 Issue 29 | p. 17 | Concentrates
Issue Date: July 20, 2015

Siegfried Transfers A Plant To Celgene

Department: Business
Keywords: custom synthesis, active pharmaceutical ingredients

Swiss fine chemicals maker Siegfried has sold a production building at its facility in Zofingen, Switzerland, to the biotech firm Celgene. The agreement builds on a contract signed 10 years ago under which Celgene has exclusive rights to capacity in Zofingen for production of the active ingredient in its multiple myeloma drug Revlimid. Separately, German and French authorities have green-lighted Siegfried’s acquisition, announced earlier this year, of three European custom synthesis sites from BASF.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment